Please check your internet connection and try again.
# Ecospirin Enteric-Coated (Aspirin)
## Overview
Ecospirin is a brand name for enteric-coated aspirin, a nonsteroidal anti-inflammatory drug (NSAID) used for its analgesic, anti-inflammatory, and antiplatelet effects. The enteric coating is designed to delay absorption until the drug reaches the small intestine, reducing gastric irritation.
## Primary Indications
* **Analgesia/Antipyresis:** Mild to moderate pain and fever.
* **Antiplatelet Therapy:** Prevention of thrombotic events (e.g., myocardial infarction, stroke) in patients with established cardiovascular disease, certain risk factors, or after procedures like coronary stenting.
## Adult Dosing
* **Analgesia/Antipyresis:** 325 mg to 650 mg orally every 4 hours as needed, or 500 mg to 1000 mg every 4 to 6 hours as needed. Maximum daily dose typically 4000 mg.
* **Antiplatelet Therapy (Primary Prevention):** Doses vary, often 75 mg to 162 mg once daily.
* **Antiplatelet Therapy (Secondary Prevention/Post-MI/Stroke Prevention):** Typically 75 mg to 162 mg once daily. Higher doses (e.g., 325 mg once daily) may be used initially in some acute settings, but long-term use favors lower doses.
* **Kawasaki Disease:** Dosing is weight-based and varies depending on the phase of illness. Consult specific guidelines.
## Pediatric Dosing
* **Analgesia/Antipyresis:** Generally **avoided** in children and adolescents due to the risk of Reye's syndrome, especially during viral illnesses. If absolutely necessary and other options are unsuitable, dose is 10-15 mg/kg/dose orally every 4-6 hours. Maximum dose: 650 mg/dose.
* **Kawasaki Disease:** Specific dosing protocols are used, typically 30-50 mg/kg/day in 4 divided doses during the acute phase, followed by 3-5 mg/kg/day once daily in the convalescent phase. These protocols often utilize higher doses and require expert guidance.
## Dose Adjustments
No specific dose adjustments are typically required for renal or hepatic impairment, however, caution is advised in severe impairment due to potential for accumulation and increased risk of adverse effects.
## Contraindications
* Hypersensitivity to aspirin, NSAIDs, or salicylates.
* History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Severe hepatic or renal impairment.
* Severe heart failure.
* Hemophilia and other hemorrhagic disorders.
## Adverse Effects
* **Common:** Dyspepsia, heartburn, nausea, abdominal pain, increased bleeding time, bruising.
* **Serious:** Gastrointestinal bleeding/perforation, tinnitus (especially with higher doses), hearing loss, renal toxicity, bronchospasm, hypersensitivity reactions, Reye's syndrome (in children/adolescents).
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity, bleeding, and potential for reduced cardioprotective effect of aspirin.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** NSAIDs can reduce their efficacy and increase risk of renal toxicity.
* **Methotrexate:** Aspirin can increase methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Aspirin can antagonize their effects.
* **Valproic Acid:** Aspirin can increase valproic acid levels.
* **Alcohol:** Increased risk of GI irritation and bleeding.
## Monitoring
* Signs and symptoms of GI bleeding (e.g., melena, hematemesis, abdominal pain).
* Signs of bleeding or bruising.
* Tinnitus or hearing changes (may indicate toxicity).
* Renal function (BUN, creatinine) in patients with risk factors or long-term high-dose use.
* Liver function in patients with hepatic impairment or suspected liver injury.
## Clinical Pearls
* The enteric coating does not eliminate the risk of GI bleeding, although it may reduce it compared to immediate-release aspirin.
* For urgent antiplatelet effects, immediate-release aspirin is preferred as enteric-coated aspirin has a delayed onset of action.
* Patients should be advised to avoid alcohol while taking aspirin.
* Discontinue aspirin at least 5-7 days before elective surgery if clinically appropriate and risk of thrombosis is acceptable.
* Always verify current prescribing information and specific product monographs, as recommendations and approved indications can vary by region and manufacturer.
